CSANZ 2020

Sponsored Symposia

12.25 - 12.55pm, Friday 11 December



Identifying high risk CV patients – a quantitative approach

Speaker: Professor Kausik Ray, Imperial College, London

This talk will explore the concept of absolute risk to determine absolute benefits from lipid lowering therapies. For instance, what is high or moderate risk and what tools are available, and why is risk assessment more important than simply looking at LDL-C levels to determine treatment thresholds.

OpSens OptoWire: Greater confidence and broader indications in coronary physiology

Moderator: Dr Greg Starmer,Cairns Hospital, QLD, Australia
Panelists: Dr Sanjeevan Pasupati - Wakaito Hospital, Hamilton, New Zealand and Dr Zsolt Piroth – Hungarian Institute of Cardiology, Budapest – Hungary

Objectives of the session:

  • To learn using clinical cases how the OptoWire guidewire from Opsens can guide revascularization decisions in patients with complex anatomy in complex settings
  • To discover how OptoWire can open new opportunities in patients with Acute MI
  • To discuss on the best physiological approach (resting or hyperemic) to assess coronary lesions in patients with Aortic Stenosis

Topic to be confirmed

Speaker: To be confirmed 

Advancing evidence on current drug eluting stents  

Speaker: Dr David Roy, NSW

High bleeding risk (HBR) patients are a large, growing, complex population that historically had little evidence to support treatment decisions. For these reasons, Medtronic initiated the Onyx ONE Month DAPT Program. ONYX ONE GLOBAL STUDY is the First prospective, randomized, 1-month DAPT trial comparing a DES to a DES in ~2,000 HBR patients. While ONYX ONE Clear added 752 HBR patients from the United States and Japan in a prospective, multicentre, single-arm trial.  Please join Dr David Roy to review the latest outcomes of the subanalysis results from three more complex subsets of the Onyx ONE program:  

  • Outcomes in High Bleeding Risk Patients with Acute Coronary Syndrome, 
  • Patients undergoing Complex PCI 
  • Patients suffering from Atrial Fibrillation (AF) patients on oral anticoagulants.